Home
Making the Case for MTET: Where Miracles Become Standard Oncology
Barnes and Noble
Making the Case for MTET: Where Miracles Become Standard Oncology
Current price: $300.00


Barnes and Noble
Making the Case for MTET: Where Miracles Become Standard Oncology
Current price: $300.00
Size: Hardcover
Loading Inventory...
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Barnes and Noble
Millions of cancer cases are diagnosed yearly. While a cure has yet to be discovered, one of the most promising new treatments is Multi-Targeted Epigenetic Therapy, or MTET.
In
Making the Case for MTET
, world-renowned oncology expert Dr. Mohammad A. Nezami introduces his revolutionary method of treating patients with advanced cancer by using a careful combination of drugs and genomic sequencing. For some patients with stage four cancer, MTET has been a lifesaving intervention.
Dr. Nezami presents 300 case studies of patients with advanced cancer that he treated over ten years of longitudinal tracking with MTET. Through meticulously documented data, lab reports, and full-color photographs to detailed genomic information, Dr. Nezami makes a compelling case for furthering MTET research and focusing on patient-centric care.
In
Making the Case for MTET
, world-renowned oncology expert Dr. Mohammad A. Nezami introduces his revolutionary method of treating patients with advanced cancer by using a careful combination of drugs and genomic sequencing. For some patients with stage four cancer, MTET has been a lifesaving intervention.
Dr. Nezami presents 300 case studies of patients with advanced cancer that he treated over ten years of longitudinal tracking with MTET. Through meticulously documented data, lab reports, and full-color photographs to detailed genomic information, Dr. Nezami makes a compelling case for furthering MTET research and focusing on patient-centric care.